137 related articles for article (PubMed ID: 37770377)
21. Lithium and clozapine-induced neutropenia/agranulocytosis.
Blier P; Slater S; Measham T; Koch M; Wiviott G
Int Clin Psychopharmacol; 1998 May; 13(3):137-40. PubMed ID: 9690982
[TBL] [Abstract][Full Text] [Related]
22. Psychopharmacology. Clozapine and agranulocytosis.
Feldman J
Psychiatr Serv; 1996 Nov; 47(11):1177-8. PubMed ID: 8916231
[No Abstract] [Full Text] [Related]
23. [Clozapine rechallenge after neutropenia in resistant schizophrenia: A review].
Simon L; Cazard F
Encephale; 2016 Aug; 42(4):346-53. PubMed ID: 27109327
[TBL] [Abstract][Full Text] [Related]
24. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.
Munro J; O'Sullivan D; Andrews C; Arana A; Mortimer A; Kerwin R
Br J Psychiatry; 1999 Dec; 175():576-80. PubMed ID: 10789357
[TBL] [Abstract][Full Text] [Related]
25. Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis.
Hazewinkel AW; Bogers JP; Giltay EJ
Gen Hosp Psychiatry; 2013; 35(5):576.e11-2. PubMed ID: 23395419
[TBL] [Abstract][Full Text] [Related]
26. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland.
Rubio JM; Kane JM; Tanskanen A; Tiihonen J; Taipale H
Lancet Psychiatry; 2024 Jun; 11(6):443-450. PubMed ID: 38697177
[TBL] [Abstract][Full Text] [Related]
27. N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia.
Combs MD; Perry PJ; Bever KA
Pharmacotherapy; 1997; 17(6):1300-4. PubMed ID: 9399615
[TBL] [Abstract][Full Text] [Related]
28. Reversible neutropenia with olanzapine following clozapine-induced neutropenia.
Thangadurai P; Jyothi KS; Gopalakrishnan R; Kuruvilla A; Jacob KS
Am J Psychiatry; 2006 Jul; 163(7):1298. PubMed ID: 16816247
[No Abstract] [Full Text] [Related]
29. Absolute Agranulocytosis After 9 Weeks of Clozapine 25 mg Daily.
Friedman JH
Clin Neuropharmacol; 2022 Jan-Feb 01; 45(1):9-10. PubMed ID: 35029864
[TBL] [Abstract][Full Text] [Related]
30. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.
Remington G; Lee J; Agid O; Takeuchi H; Foussias G; Hahn M; Fervaha G; Burton L; Powell V
Expert Opin Drug Saf; 2016 Sep; 15(9):1193-203. PubMed ID: 27207070
[TBL] [Abstract][Full Text] [Related]
31. [Hematological Evaluation and Monitoring in Adult Patients Diagnosed With Schizophrenia].
Tamayo Martínez N; Bohórquez Peñaranda AP; García Valencia J; Jaramillo González LE; Ávila MJ; Gómez-Restrepo C; Arenas González ML
Rev Colomb Psiquiatr; 2015; 44(3):131-6. PubMed ID: 26578412
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring.
Sultan RS; Olfson M; Correll CU; Duncan EJ
J Clin Psychiatry; 2017; 78(8):e933-e939. PubMed ID: 28742291
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of clozapine monitoring after the first 6 months.
Zhang M; Owen RR; Pope SK; Smith GR
Arch Gen Psychiatry; 1996 Oct; 53(10):954-8. PubMed ID: 8857873
[TBL] [Abstract][Full Text] [Related]
34. Haematological toxicity of clozapine and some other drugs used in psychiatry.
Nooijen PM; Carvalho F; Flanagan RJ
Hum Psychopharmacol; 2011 Mar; 26(2):112-9. PubMed ID: 21416507
[TBL] [Abstract][Full Text] [Related]
35. Late-onset clozapine-induced agranulocytosis in a patient with comorbid multiple sclerosis.
Raveendranathan D; Sharma E; Venkatasubramanian G; Rao MG; Varambally S; Gangadhar BN
Gen Hosp Psychiatry; 2013; 35(5):574.e5-6. PubMed ID: 22902258
[TBL] [Abstract][Full Text] [Related]
36. [Risk minimization evolution of agranulocytosis caused by the administration of pharmaceutical products containing Clozapine in Argentina].
Bergman M; Bignone I; Bisio A; Bologna V; Sabatini A
Vertex; 2011; 22(96):94-7. PubMed ID: 21977603
[TBL] [Abstract][Full Text] [Related]
37. Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Hong X; Wang X
Am J Psychiatry; 2001 Oct; 158(10):1736-7. PubMed ID: 11579015
[No Abstract] [Full Text] [Related]
38. [Patient knowledge regarding Clozapine-induced agranulocytosis].
Haberfellner EM; Rittmannsberger H
Psychiatr Prax; 2006 May; 33(4):194-6. PubMed ID: 16680627
[No Abstract] [Full Text] [Related]
39. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
Alvir JM; Lieberman JA; Safferman AZ; Schwimmer JL; Schaaf JA
N Engl J Med; 1993 Jul; 329(3):162-7. PubMed ID: 8515788
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case report.
Spencer BW; Williams HR; Gee SH; Whiskey E; Rodrigues JP; Mijovic A; MacCabe JH
J Psychopharmacol; 2012 Sep; 26(9):1280-2. PubMed ID: 22719015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
